Hydrogel ink for anticancer and tissue regeneration, hydrogel scaffold for anticancer and tissue regeneration, preparation method therefor, and tissue therapy method using same

The hydrogel ink and scaffold address the issue of tissue damage in photothermal cancer treatments by using gallium and DNA to target and regenerate tissue, achieving effective cancer treatment with minimal collateral damage.

WO2026235453A1PCT designated stage Publication Date: 2026-11-12INDUSTRY UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096534
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-04-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing anticancer treatments using photothermal reactions often damage surrounding normal tissue during cancer necrosis, and there is a need for improved methods to regenerate tissue after cancer treatment.

Method used

A hydrogel ink and scaffold are developed that incorporate a functional hydrogel, an anticancer substance (gallium) supported on the hydrogel for photothermal reaction, and a tissue regeneration substance (DNA) to control release rate and enhance dispersibility, viscosity, and elasticity, allowing for targeted cancer treatment with minimal damage to normal tissue.

Benefits of technology

The hydrogel support effectively kills cancer cells through photothermal reaction while regenerating tissue, minimizing damage to surrounding tissue and controlling the release of regeneration materials, thus addressing the limitations of conventional treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096534_12112026_PF_FP_ABST
    Figure KR2026096534_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a method for preparing a hydrogel scaffold for anticancer and tissue regeneration, comprising the steps of: mixing a functional hydrogel and a tissue regeneration material so as to prepare an ink source; adding an anticancer material to the ink source so as to prepare a hydrogel ink for anticancer and tissue regeneration; mixing the hydrogel ink for anticancer and tissue regeneration and a curing agent so as to prepare a semi-solid hydrogel ink; and printing and curing the semi-solid hydrogel ink so as to prepare a hydrogel scaffold for anticancer and tissue regeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Hydrogel ink for anticancer and tissue regeneration, hydrogel scaffold for anticancer and tissue regeneration, method of manufacturing the same, and tissue treatment method using the same

[0001] The present application relates to a hydrogel ink for anticancer and tissue regeneration, a hydrogel scaffold for anticancer and tissue regeneration, a method for manufacturing the same, and a method for tissue treatment using the same. More specifically, it relates to a hydrogel ink for anticancer and tissue regeneration, a hydrogel scaffold for anticancer and tissue regeneration, a method for manufacturing the same, and a method for tissue treatment using the same, which regenerates tissue not only for anticancer but also after anticancer.

[0002]

[0003] In the past, methods utilizing photothermal reactions in anticancer treatment were known. For example, Korean Patent Publication No. 10-2023-0050952 discloses a method for manufacturing a porous reduced graphene oxide nanocomposite for targeting cancer cells for photothermal therapy and photodynamic therapy, wherein the method comprises a first step of introducing a porous silica layer to graphene oxide to provide a graphene oxide silica nanocomposite, a second step of reducing the graphene oxide silica to provide a reduced graphene oxide silica nanocomposite, and a third step of binding folic acid to the reduced graphene oxide silica nanocomposite.As another example, Korean Registered Patent Publication No. 10-2692009 describes a phospholipid-photothermal nanoparticle with an antibody bound to its surface, comprising a phospholipid membrane in which photothermal nanoparticles are captured, and an antibody or a fragment thereof specific to a surface protein of a cancer cell bound to the surface of said phospholipid membrane, wherein the phospholipid membrane comprises any one selected from the group consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-Dipalmitoyl-sn-glycero-3-phosphorylglycerol (DPPG), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and phosphorylglycerol (PG), phosphocholine (PC) and 1,2-Dipalmitoyl-sn-glycero-3-phosphorylglycerol (DPPG), phosphocholine (PC) and phosphorylglycerol (PG), and phosphocholine (PC). A phospholipid-photothermal nanoparticle with an antibody bound to its surface is disclosed, which further comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethyleneglycol)-2000](DSPE-PEG2000-maleimide).

[0004] However, anticancer treatment utilizing such photothermal reactions may have limitations in that it damages normal tissue surrounding the cancerous tissue during the necrosis of the cancerous tissue.

[0005] Therefore, there is a need for tissue regeneration methods to follow cancer treatment.

[0006]

[0007] The technical problem that the present application aims to solve is to provide a hydrogel ink for anticancer and tissue regeneration that regenerates tissue after anticancer as well as anticancer, a hydrogel scaffold for anticancer and tissue regeneration, a method for manufacturing the same, and a tissue treatment method using the same.

[0008] Another technical problem that the present application aims to solve is to provide a hydrogel ink for anticancer and tissue regeneration with excellent dispersibility of anticancer substances, a hydrogel scaffold for anticancer and tissue regeneration, a method for manufacturing the same, and a method for tissue treatment using the same.

[0009] Another technical problem that the present application aims to solve is to provide a hydrogel ink for anticancer and tissue regeneration that controls the release rate of a tissue regeneration material, a hydrogel scaffold for anticancer and tissue regeneration, a method for manufacturing the same, and a tissue treatment method using the same.

[0010] The technical problems that this application aims to solve are not limited to those described above.

[0011]

[0012] To solve the above technical problem, the present application provides a method for manufacturing a hydrogel scaffold for anticancer and tissue regeneration.

[0013] According to one embodiment, the method for manufacturing a hydrogel support for anticancer and tissue regeneration may include the steps of: mixing a functional hydrogel and a tissue regeneration material to produce an ink source; adding an anticancer material to the ink source to produce a hydrogel ink for anticancer and tissue regeneration; mixing the hydrogel ink for anticancer and tissue regeneration with a curing agent to produce a semi-solid hydrogel ink; and printing and curing the semi-solid hydrogel ink to produce a hydrogel support for anticancer and tissue regeneration.

[0014] According to one embodiment, the functional hydrogel can be prepared by the steps of: dissolving a gelling polymer to prepare a gelling polymer source; and reacting the gelling polymer source with a functionalizing agent comprising epoxy groups and silane groups to prepare the functional hydrogel.

[0015] According to one embodiment, the gelling polymer comprises alginate, and the functionalizing agent may comprise 3-glycidoxypropyl trimethoxysilane (GPTMS).

[0016] According to one embodiment, the anticancer substance comprises gallium, and the gallium may be provided in an amount of more than 1 g and less than 10 g per 100 g of water.

[0017] According to one embodiment, as the amount of gallium increases, viscosity and elasticity increase, and the release of the tissue regeneration material may be slowed down.

[0018] According to one embodiment, the anticancer substance may be prepared by the steps of: preparing a first anticancer source; heat-treating the first anticancer source; ultrasonically treating the heat-treated first anticancer source in a low-temperature atmosphere to produce a second anticancer source; and rapidly freeze-drying the second anticancer source to produce the anticancer substance.

[0019] According to one embodiment, the first anticancer source may be in liquid form, and the second anticancer source may be in powder form.

[0020] According to one embodiment, the curing agent may include calcium chloride.

[0021]

[0022] To solve the above technical problem, the present application provides a hydrogel support for anticancer and tissue regeneration.

[0023] According to one embodiment, the hydrogel support for anticancer and tissue regeneration may include a functional hydrogel, an anticancer substance supported on the functional hydrogel that acts as an anticancer agent through a photothermal reaction, and a tissue regeneration substance supported on the functional hydrogel that regenerates tissue after the anticancer action of the anticancer substance.

[0024] According to one embodiment, the anticancer substance can increase the viscosity and elasticity of the functional hydrogel and slow down the release of the tissue regeneration substance.

[0025] According to one embodiment, the functional hydrogel comprises alginate functionalized with 3-glycidoxypropyltrimethoxysilane (GPTMS), the anticancer substance comprises gallium, and the tissue regeneration substance may comprise DNA (deoxyribonucleic acid).

[0026]

[0027] To solve the above technical problem, the present application provides a tissue treatment method using a hydrogel scaffold for anticancer and tissue regeneration.

[0028] According to one embodiment, a tissue treatment method using the hydrogel support for anticancer and tissue regeneration may include the steps of providing the hydrogel support for anticancer and tissue regeneration to cancer tissue, the step of the anticancer substance reacting photothermally by light irradiation to act as an anticancer agent in the cancer tissue, and the step of the tissue regeneration substance regenerating tissue in the tissue after the anticancer agent's action.

[0029] According to one embodiment, the release rate of the tissue regeneration material can be controlled by the anticancer material.

[0030]

[0031] To solve the above technical problem, the present application provides a hydrogel ink for anticancer and tissue regeneration.

[0032] According to one embodiment, the hydrogel ink for anticancer and tissue regeneration may include a functional hydrogel, an anticancer substance supported on the functional hydrogel that acts as an anticancer agent through a photothermal reaction, and a tissue regeneration substance that combines with the functional hydrogel to regenerate tissue.

[0033]

[0034] According to an embodiment of the present application, a method for manufacturing a hydrogel support for anticancer and tissue regeneration may be provided, comprising the steps of: mixing a functional hydrogel and a tissue regeneration material to manufacture an ink source; adding an anticancer substance to the ink source to manufacture a hydrogel ink for anticancer and tissue regeneration; mixing the hydrogel ink for anticancer and tissue regeneration and a curing agent to manufacture a semi-solid hydrogel ink; and printing and curing the semi-solid hydrogel ink to manufacture a hydrogel support for anticancer and tissue regeneration.

[0035] Accordingly, a hydrogel support for anticancer and tissue regeneration may be provided, comprising the above-mentioned functional hydrogel, the above-mentioned anticancer substance supported on the above-mentioned functional hydrogel and acting as an anticancer agent through a photothermal reaction, and the above-mentioned tissue regeneration substance supported on the above-mentioned functional hydrogel and regenerating tissue after the anticancer action of the above-mentioned anticancer substance.

[0036]

[0037] According to an embodiment of the present application, since the anticancer and tissue regeneration hydrogel support comprises the anticancer substance supported on the functional hydrogel, when light is irradiated, the anticancer substance can perform an anticancer effect by undergoing a photothermal reaction. More specifically, when infrared light, for example, light with a wavelength of 808 nm, is irradiated, the anticancer substance can undergo a photothermal reaction, and accordingly, cancer can be killed. According to an embodiment of the present application, since the anticancer substance is in the form of a powder with a nano-level size, for example, 200 nm, and the gallium is included in an amount of more than 1 g to less than 10 g per 100 g of water, more specifically, for example, 5 g per 100 g of water, the dispersibility in the functional hydrogel can be excellent, and as a result, the anticancer and tissue regeneration hydrogel support can have excellent cancer killing characteristics. Furthermore, the anticancer and tissue regeneration hydrogel support can have low cytotoxicity.

[0038] In addition, according to an embodiment of the present application, the hydrogel support for anticancer and tissue regeneration can slow down the release rate of the tissue regeneration material because it includes the anticancer material supported on the functional hydrogel.

[0039] Accordingly, according to the embodiments of the present application, the problem of the release rate of DNA supported on conventional hydrogels being too fast can be resolved.

[0040] Furthermore, the above-mentioned hydrogel support for anticancer and tissue regeneration may have increased viscosity and elasticity because it includes the anticancer substance supported on the functional hydrogel.

[0041] According to an embodiment of the present application, the hydrogel scaffold for anticancer and tissue regeneration comprises the tissue regeneration material, and thus can regenerate tissue after the anticancer action of the anticancer material.

[0042] That is, according to an embodiment of the present application, since tissue regeneration using the tissue regeneration material follows anticancer treatment using the anticancer material, the problem of normal tissue surrounding the cancer tissue being damaged during the necrosis of the cancer tissue in conventional anticancer treatment using photothermal reactions can be resolved.

[0043]

[0044] FIG. 1 is a drawing for explaining a method for manufacturing a hydrogel ink for anticancer and tissue regeneration according to an embodiment of the present application.

[0045] FIG. 2 is a drawing for explaining in more detail a method for manufacturing a hydrogel ink for anticancer and tissue regeneration according to an embodiment of the present application.

[0046] FIG. 3 is a drawing for explaining a method for manufacturing a functional hydrogel according to an embodiment of the present application.

[0047] FIG. 4 is a drawing for explaining in more detail a method for manufacturing a functional hydrogel according to an embodiment of the present application.

[0048] FIG. 5 is a drawing for explaining a method for manufacturing an anticancer substance according to an embodiment of the present application.

[0049] FIG. 6 is a drawing for explaining in more detail a method for manufacturing an anticancer substance according to an embodiment of the present application.

[0050] FIG. 7 is a drawing for explaining a method for manufacturing a hydrogel support for anticancer and tissue regeneration according to an embodiment of the present application.

[0051] FIG. 8 is a drawing for explaining a tissue treatment method using a hydrogel support for anticancer and tissue regeneration according to an embodiment of the present application.

[0052] FIG. 9 is a drawing showing scanning electron microscope (SEM) images of anticancer substances according to Experimental Examples 1 to 3 of the present application.

[0053] FIG. 10 is a diagram showing the particle size and distribution of anticancer substances according to Experimental Examples 1 to 3 of the present application.

[0054] FIG. 11 is a diagram showing the dynamic light scattering (DLS) of anticancer substances according to Experimental Examples 1 to 3 of the present application.

[0055] FIG. 12 is a diagram showing the zeta potential of anticancer substances according to Experimental Examples 1 to 3 of the present application.

[0056] FIG. 13 is a diagram showing (a) a transmission electron microscope (TEM) image and (b to e) scanning transmission electron microscope (SETM) images of a hydrogel ink for anticancer and tissue regeneration according to Experimental Example 3 of the present application.

[0057] FIG. 14 is a drawing showing photographs (a~d) before mixing the curing agent and (e~h) after mixing the curing agent according to experimental examples of the present application.

[0058] FIG. 15 is a diagram showing the viscosity according to Experimental Examples 1 to 3 of the present application.

[0059] FIG. 16 is a figure showing the loss modulus and storage modulus according to Experimental Examples 1 to 3 of the present application.

[0060] FIG. 17 is a drawing showing a photograph of a printed material according to Experimental Example 2 of the present application.

[0061] FIG. 18 is a diagram showing x-ray diffraction (XRD) according to Experimental Examples 1 to 3 of the present application.

[0062] FIG. 19 is a diagram showing the tissue regeneration material release behavior of a hydrogel support for anticancer and tissue regeneration according to Experimental Examples 1 to 3 of the present application.

[0063] FIG. 20 is a diagram showing the photothermal reaction of a hydrogel support for anticancer and tissue regeneration according to Experimental Examples 1 to 3 of the present application.

[0064] FIG. 21 is a diagram showing the cytotoxicity of hydrogel supports for anticancer and tissue regeneration according to Experimental Examples 1 to 3 of the present application.

[0065]

[0066] Hereinafter, preferred embodiments of the present application will be described in detail with reference to the attached drawings. However, the technical concept of the present application is not limited to the embodiments described herein and may be embodied in other forms. Rather, the embodiments introduced herein are provided to ensure that the disclosed content is thorough and complete and to ensure that the concept of the present application is sufficiently conveyed to those skilled in the art.

[0067] In this specification, when a component is described as being on another component, it means that it may be formed directly on the other component or that a third component may be interposed between them. Additionally, in the drawings, the thicknesses of shapes and regions are exaggerated for the effective description of the technical content.

[0068] Additionally, although terms such as first, second, third, etc., have been used to describe various components in the various embodiments of this specification, these components should not be limited by such terms. These terms are used merely to distinguish one component from another. Accordingly, what is referred to as the first component in one embodiment may be referred to as the second component in another embodiment. Each embodiment described and illustrated herein also includes its complementary embodiment. Furthermore, in this specification, "and / or" is used to mean including at least one of the components listed before and after it.

[0069] In the specification, singular expressions include plural expressions unless the context clearly indicates otherwise. Furthermore, terms such as "include" or "have" are intended to specify the existence of the features, numbers, steps, components, or combinations thereof described in the specification, and should not be understood as excluding the existence or addition of one or more other features, numbers, steps, components, or combinations thereof. Additionally, in this specification, "connection" is used to include both indirectly connecting multiple components and directly connecting them.

[0070] Additionally, terms such as “…part,” “…unit,” and “module” described in the specification refer to a unit that processes at least one function or operation, and this may be implemented in hardware, software, or a combination of hardware and software.

[0071] Furthermore, in describing the present application below, if it is determined that a detailed description of related known functions or configurations could unnecessarily obscure the essence of the application, such detailed description will be omitted.

[0072]

[0073] FIG. 1 is a drawing for explaining a method for manufacturing a hydrogel ink for anticancer and tissue regeneration according to an embodiment of the present application; FIG. 2 is a drawing for explaining in more detail a method for manufacturing a hydrogel ink for anticancer and tissue regeneration according to an embodiment of the present application; FIG. 3 is a drawing for explaining a method for manufacturing a functional hydrogel according to an embodiment of the present application; FIG. 4 is a drawing for explaining in more detail a method for manufacturing a functional hydrogel according to an embodiment of the present application; FIG. 5 is a drawing for explaining a method for manufacturing an anticancer substance according to an embodiment of the present application; FIG. 6 is a drawing for explaining in more detail a method for manufacturing an anticancer substance according to an embodiment of the present application; FIG. 7 is a drawing for explaining a method for manufacturing a hydrogel support for anticancer and tissue regeneration according to an embodiment of the present application; and FIG. 8 is a drawing for explaining a tissue treatment method using a hydrogel support for anticancer and tissue regeneration according to an embodiment of the present application.

[0074] Referring to FIGS. 1 and 2, a functional hydrogel (10) and a tissue regeneration material (30) are mixed to produce an ink source (not shown) (S110).

[0075] According to one embodiment with reference to FIGS. 3 and 4, the functional hydrogel (10) can be prepared by dissolving a gelling polymer (11) to produce a gelling polymer source (12) (S111), and reacting the gelling polymer source (12) with a functionalizing agent (13) containing epoxy groups and silane groups (S112). More specifically, for example, the gelling polymer (11) may be alginate, and the functionalizing agent (13) may be 3-glycidoxypropyl trimethoxysilane (GPTMS). The alginate used as the gelling polymer (11) is a biocompatible polymer and can support the anticancer substance (20) and tissue regeneration substance (30) described later. 3-glycidoxypropyltrimethoxysilane (GPTMS) as the above functionalizing agent (13) can form a covalent bond with alginate through the epoxy group and form a Si-O-Si network through Si-OH condensation through the silane group, thereby functionalizing the gelling polymer (11).

[0076] According to one embodiment, the functional hydrogel (10) and the tissue regeneration material (30) may be mixed before the anticancer material (20) described later.

[0077] Accordingly, the functional hydrogel (10) and the tissue regeneration material (30) are uniformly combined, so that the ink source can be manufactured.

[0078] In contrast, if the functional hydrogel (10) and the anticancer substance (20) described later are mixed before the tissue regeneration substance (30), the functional hydrogel (10) and the tissue regeneration substance (30) may not be substantially uniformly combined.

[0079] However, according to an embodiment of the present application, the functional hydrogel (10) and the tissue regeneration material (30) may be mixed before the anticancer material (20) described later, and accordingly, the functional hydrogel (10) and the tissue regeneration material (30) may be uniformly combined to produce the ink source.

[0080] Referring further to FIGS. 1 and FIGS. 2, an anticancer substance (20) is added to the ink source to produce a hydrogel ink (100) for anticancer and tissue regeneration (S120).

[0081] According to one embodiment with reference to FIGS. 5 and 6, the anticancer substance (20) may be prepared by preparing a first anticancer source (21) (S121), heat-treating the first anticancer source (21) (S122), ultrasonically treating the heat-treated first anticancer source (22) in a low-temperature atmosphere to produce a second anticancer source (23) (S123), and rapidly freeze-drying the second anticancer source (23) (S124). More specifically, for example, the anticancer substance (20) may be gallium.

[0082] According to one embodiment, the first anticancer source (21) may be in a liquid state, and the second anticancer source (23) may be in a powder state. More specifically, gallium with a melting point of 29.76 ℃ is in a solid state at room temperature, i.e., 25 ℃, but can be easily converted into a liquid state.

[0083] Accordingly, when the liquid first anticancer source (21) is heat-treated and then ultrasonically treated in a low-temperature atmosphere, for example, 10°C, the second anticancer source (23) can be produced in a powder form with a nano-level size, for example, 200 nm.

[0084] Accordingly, the anticancer substance (20) prepared from the second anticancer source (23), which is a nano-level powder, may have excellent dispersibility.

[0085] In contrast, if the heat-treated first anticancer source (21) is not ultrasonically treated in a low-temperature atmosphere, that is, if the temperature of the heat-treated first anticancer source (21) is higher than 29.76 ℃, the gallium may be converted into a liquid state.

[0086] As a result, aggregation and clumping between gallium particles may occur.

[0087] However, according to an embodiment of the present application, the liquid first anticancer source (21) can be ultrasonically treated in a low-temperature atmosphere after being heat-treated, and thereby, the anticancer substance (20) with excellent dispersibility can be produced from the second anticancer source (23) which is a nano-level powder.

[0088] According to one embodiment, in the preparation of the hydrogel ink (100) for anticancer and tissue regeneration, the gallium may be provided, for example, in an amount greater than 1 g and less than 10 g per 100 g of water. More specifically, for example, the gallium may be provided in an amount of 5 g per 100 g of water.

[0089] Accordingly, the dispersibility of the anticancer substance (20) may be high in the hydrogel ink (100) for anticancer and tissue regeneration and in the hydrogel support for anticancer and tissue regeneration manufactured from the hydrogel ink (100) for anticancer and tissue regeneration.

[0090] In contrast, if the gallium is provided in an amount of 1 g or less or 10 g or more per 100 g of water, the dispersibility of the anticancer substance (20) may be low.

[0091] However, according to an embodiment of the present application, in the preparation of the hydrogel ink (100) for anticancer and tissue regeneration, the gallium may be provided, for example, in an amount of more than 1 g and less than 10 g per 100 g of water, more specifically, for example, in an amount of 5 g per 100 g of water.

[0092] Accordingly, the dispersibility of the anticancer substance (20) may be high in the hydrogel ink (100) for anticancer and tissue regeneration and in the hydrogel support for anticancer and tissue regeneration manufactured from the hydrogel ink (100) for anticancer and tissue regeneration.

[0093] In addition, in the manufacture of the above-mentioned hydrogel ink (100) for anticancer and tissue regeneration, if the gallium is provided in an amount of, for example, more than 1 g and less than 10 g per 100 g of water, more specifically, for example, 5 g per 100 g of water, the cytotoxicity of the above-mentioned hydrogel ink (100) and the hydrogel support for anticancer and tissue regeneration manufactured from the above-mentioned hydrogel ink (100) may be low.

[0094] In contrast, if the above gallium is provided in amounts of 10 g or more so that the total amount with water is 100 g, the cytotoxicity may be high.

[0095] However, according to an embodiment of the present application, in the preparation of the hydrogel ink (100) for anticancer and tissue regeneration, the gallium may be provided, for example, in an amount of more than 1 g and less than 10 g per 100 g of water, more specifically, for example, in an amount of 5 g per 100 g of water, and accordingly, the cytotoxicity of the hydrogel ink (100) for anticancer and tissue regeneration and the hydrogel support for anticancer and tissue regeneration prepared from the hydrogel ink (100) for anticancer and tissue regeneration may be low.

[0096] According to one embodiment, the release rate of the tissue regeneration material (30) can be controlled by the anticancer substance (20). More specifically, in the manufacture of the hydrogel ink (100) for anticancer and tissue regeneration, as the amount of the added anticancer substance (20) increases, the release of the tissue regeneration material (30) from the hydrogel support for anticancer and tissue regeneration manufactured from the hydrogel ink (100) for anticancer and tissue regeneration can be slowed down. Furthermore, in the manufacture of the hydrogel ink (100) for anticancer and tissue regeneration, as the amount of the added anticancer substance (20) increases, the viscosity and elasticity of the hydrogel support for anticancer and tissue regeneration manufactured from the hydrogel ink (100) for anticancer and tissue regeneration can be increased.

[0097]

[0098] According to the method for manufacturing a hydrogel ink for anticancer and tissue regeneration according to the embodiment of the present application described above, a hydrogel ink (100) for anticancer and tissue regeneration may be provided, comprising: a functional hydrogel (10); an anticancer substance (20) that acts as an anticancer agent through a photothermal reaction and is supported on the functional hydrogel (10); and a tissue regeneration substance (30) that combines with the functional hydrogel (10) to regenerate tissue. For example, the functional hydrogel (10) may be alginate functionalized with 3-glycidoxypropyltrimethoxysilane (GPTMS), the anticancer substance (20) may be gallium, and the tissue regeneration substance (30) may be DNA (deoxyribonucleic acid).

[0099] According to one embodiment, the hydrogel ink (100) for anticancer and tissue regeneration contains the anticancer substance (20) supported on the functional hydrogel (10), so when light is irradiated, the anticancer substance (20) can react photothermally and have an anticancer effect. More specifically, when infrared light, for example, light with a wavelength of 808 nm, is irradiated, the anticancer substance (20) can react photothermally, and accordingly, cancer can be killed. According to an embodiment of the present application, the anticancer substance (20) is in the form of a powder with a nano-level size, for example, 200 nm, and the gallium is included in an amount of more than 1 g to less than 10 g per 100 g of water, more specifically, for example, 5 g per 100 g of water, so the dispersibility in the functional hydrogel (10) can be excellent, and as a result, the hydrogel ink (100) for anticancer and tissue regeneration can have excellent cancer-killing properties. Furthermore, the hydrogel ink (100) for anticancer and tissue regeneration can have low cytotoxicity.

[0100] In addition, according to one embodiment, the hydrogel ink (100) for anticancer and tissue regeneration can control the release rate of the tissue regeneration material (30) because it includes the anticancer substance (20) supported on the functional hydrogel (10).

[0101] Accordingly, according to the embodiments of the present application, the problem of the release rate of DNA supported on conventional hydrogels being too fast can be resolved.

[0102] According to one embodiment, the hydrogel ink (100) for anticancer and tissue regeneration contains the tissue regeneration material (30), so it can regenerate tissue after the anticancer action of the anticancer material (20).

[0103] That is, according to an embodiment of the present application, since tissue regeneration through the tissue regeneration material (30) follows anticancer treatment through the anticancer material (20), the problem of normal tissue surrounding the cancer tissue being damaged during necrosis of the cancer tissue in conventional anticancer treatment using photothermal reactions can be resolved.

[0104]

[0105] According to an embodiment of the present application, an anticancer and tissue regeneration hydrogel support can be manufactured from the anticancer and tissue regeneration hydrogel ink (100). More specifically, referring to FIG. 7, the anticancer and tissue regeneration hydrogel ink (100) and a curing agent can be mixed to manufacture a semi-solid hydrogel ink (S130). The curing agent may be, for example, calcium chloride.

[0106] According to one embodiment, the semi-solid hydrogel ink may have semi-solid properties due to the curing agent. However, since the semi-solid hydrogel ink contains the curing agent, the semi-solid properties may be converted to solid properties over time. In this specification, semi-solid may mean a semi-solid, that is, an intermediate state between liquid and solid, and solid may mean a solid state.

[0107] In other words, for smooth printing of the above semi-solid hydrogel ink, the above anticancer and tissue regeneration hydrogel ink (100) and the curing agent may need to be mixed and printed within a few hours.

[0108] In contrast, if the above-mentioned anticancer and tissue regeneration hydrogel ink (100) and the above-mentioned curing agent are mixed and printed for more than a few hours, the above-mentioned semi-solid state may change to a solid state over time, and the ink may not be printed substantially.

[0109] However, according to an embodiment of the present application, the hydrogel ink (100) for anticancer and tissue regeneration and the curing agent can be mixed and printed within a few hours, and accordingly, the printing of the semi-solid hydrogel ink can be smooth.

[0110] Referring further to FIG. 7, the semi-solid hydrogel ink can be printed and cured to manufacture a hydrogel scaffold for anticancer and tissue regeneration (S140).

[0111] According to one embodiment, the semi-solid hydrogel ink can be printed using a printer, specifically a 3D printer. When the semi-solid hydrogel ink is printed and several hours have passed, the printed material can be cured by the curing agent over time.

[0112] Accordingly, the above-mentioned hard gel scaffold for anticancer and tissue regeneration can be manufactured.

[0113]

[0114] According to the method for manufacturing a hydrogel support for anticancer and tissue regeneration according to the embodiment of the present application described above, a hydrogel support for anticancer and tissue regeneration may be provided, comprising: the functional hydrogel (10); the anticancer substance (20) supported on the functional hydrogel (10) and acting as an anticancer agent through a photothermal reaction; and the tissue regeneration substance (30) supported on the functional hydrogel (10) and regenerating tissue after the anticancer action of the anticancer substance (20). For example, the functional hydrogel (10) may be alginate functionalized with 3-glycidoxypropyltrimethoxysilane (GPTMS), the anticancer substance (20) may be gallium, and the tissue regeneration substance (30) may be DNA.

[0115] According to one embodiment, the anticancer and tissue regeneration hydrogel support comprises the anticancer substance (20) supported on the functional hydrogel (10), so that when light is irradiated, the anticancer substance (20) can react photothermally and perform an anticancer action. More specifically, when infrared light, for example, light with a wavelength of 808 nm, is irradiated, the anticancer substance (20) can react photothermally, and accordingly, cancer can be killed. According to an embodiment of the present application, the anticancer substance (20) is in the form of a powder with a nano-level size, for example, 200 nm, and the gallium is included in an amount of more than 1 g to less than 10 g per 100 g of water, more specifically, for example, 5 g per 100 g of water, so that it can have excellent dispersibility in the functional hydrogel (10), and as a result, the anticancer and tissue regeneration hydrogel support can have excellent cancer killing characteristics. Furthermore, the above-mentioned hard gel scaffold for anticancer and tissue regeneration may have low cytotoxicity.

[0116] In addition, according to one embodiment, the anticancer and tissue regeneration hydrogel support may slow down the release rate of the tissue regeneration material (30) because it includes the anticancer substance (20) supported on the functional hydrogel (10).

[0117] Accordingly, according to the embodiments of the present application, the problem of the release rate of DNA supported on conventional hydrogels being too fast can be resolved.

[0118] Furthermore, the above-mentioned hydrogel support for anticancer and tissue regeneration may have increased viscosity and elasticity because it includes the anticancer substance (20) supported on the functional hydrogel (10).

[0119] According to one embodiment, the hard gel support for anticancer and tissue regeneration includes the tissue regeneration material (30), so that tissue can be regenerated after the anticancer action of the anticancer material (20).

[0120] That is, according to an embodiment of the present application, since tissue regeneration through the tissue regeneration material (30) follows anticancer treatment through the anticancer material (20), the problem of normal tissue surrounding the cancer tissue being damaged during necrosis of the cancer tissue in conventional anticancer treatment using photothermal reactions can be resolved.

[0121]

[0122] According to an embodiment of the present application, a tissue can be treated using the hydrogel support for anticancer and tissue regeneration. More specifically, with reference to FIG. 8, the hydrogel support for anticancer and tissue regeneration can be provided to cancer tissue (S210).

[0123] Referring further to FIG. 8, the anticancer substance (20) can have an anticancer effect on the cancer tissue by photothermal reaction upon light irradiation (S220). Since the hydrogel support for anticancer and tissue regeneration contains the anticancer substance (20) supported on the functional hydrogel (10), when light is irradiated, the anticancer substance (20) can have an anticancer effect by photothermal reaction. More specifically, when infrared light, for example, light with a wavelength of 808 nm, is irradiated, the anticancer substance (20) can have a photothermal reaction, and accordingly, the cancer can be killed. According to an embodiment of the present application, the anticancer substance (20) is in the form of a powder with a nano-level size, for example, 200 nm, and the gallium is included in an amount of more than 1 g to less than 10 g per 100 g of water, more specifically, for example, 5 g per 100 g of water, so the dispersibility in the functional hydrogel (10) can be excellent, and as a result, the anticancer and tissue regeneration hydrogel support can have excellent cancer-killing properties. Furthermore, the anticancer and tissue regeneration hydrogel support can have low cytotoxicity. In addition, since the anticancer and tissue regeneration hydrogel support contains the anticancer substance (20) supported on the functional hydrogel (10), the release rate of the tissue regeneration substance (30) can be slowed down.

[0124] Referring further to FIG. 8, the tissue regeneration material (30) can regenerate tissue in the tissue after the anticancer action of the anticancer substance (20) (S230). In other words, the hard gel support for anticancer and tissue regeneration can regenerate tissue after the anticancer action of the anticancer substance (20) because it contains the tissue regeneration material (30). That is, according to the embodiment of the present application, tissue regeneration through the tissue regeneration material (30) can follow after anticancer action through the anticancer substance (20), and thereby, the anticancer treatment effect can be maximized.

[0125]

[0126] Specific experimental examples and characteristic evaluation results according to the embodiments of the present application are described below.

[0127]

[0128] Preparation of a hydrogel scaffold for anticancer and tissue regeneration (ex1) according to Experimental Example 1

[0129] 1 g of liquid gallium per 100 g of water was dispersed in purified water to prepare the first anticancer source (21) in liquid form. The first anticancer source (21) in liquid form was heat-treated in a 40°C oven for 30 minutes. The heat-treated first anticancer source (22) was ultrasonically treated with a tip ultrasonic device for 10 minutes at a frequency of 20 kHz and an amplitude of 40% in a 10°C atmosphere to produce the second anticancer source (23) in powder form with a particle diameter of approximately 200 nm. The second anticancer source (23) dispersed in the aqueous phase was rapidly frozen in an ultra-low temperature refrigerator at -60°C and then freeze-dried to produce the anticancer substance (20), which is gallium nanoparticle powder.

[0130] 3 g of alginate powder as the gelling polymer (11) was added to purified water per 100 g of water, stirred and dissolved for 30 minutes to prepare the gelling polymer source (12). The gelling polymer source (12) and 3-glycidoxypropyltrimethoxysilane (GPTMS) were added in a molar ratio of 10:1 relative to alginate, and reacted at 50°C for 3 days to prepare the functional hydrogel (10).

[0131] The ink source was prepared by mixing 0.1 g of DNA as the tissue regeneration material (30) per 100 g of the functional hydrogel (10). The anticancer substance (20) was added to the ink source to prepare the hydrogel ink (100) for anticancer and tissue regeneration.

[0132] The above-mentioned hydrogel ink for anticancer and tissue regeneration (100) was loaded into a syringe, and calcium chloride was loaded as a curing agent in a volume ratio of 3:2 relative to the above-mentioned hydrogel ink for anticancer and tissue regeneration (100), and then uniformly mixed using a syringe mixing tube to produce the above-mentioned semi-solid hydrogel ink.

[0133] Using a 3D printer, the above semi-solid hydrogel ink was printed and cured over time to produce a hydrogel scaffold (ex1) for anticancer and tissue regeneration according to Experimental Example 1.

[0134]

[0135] Preparation of a hydrogel scaffold for anticancer and tissue regeneration (ex2) according to Experimental Example 2

[0136] In the above-described Experimental Example 1, 5 g of liquid gallium was dispersed per 100 g of water to prepare a hydrogel support (ex2) for anticancer and tissue regeneration according to Experimental Example 2.

[0137]

[0138] Preparation of a hydrogel scaffold for anticancer and tissue regeneration (ex3) according to Experimental Example 3

[0139] In the above-described Experimental Example 1, 10 g of liquid gallium was dispersed per 100 g of water to prepare a hydrogel support (ex3) for anticancer and tissue regeneration according to Experimental Example 3.

[0140]

[0141] The above-described experimental examples 1 to 3 (ex1~ex3) can be summarized as shown in Table 1 below.

[0142] Quantity of Gallium Experiment 1 (ex1) 1 g Experiment 2 (ex2) 5 g Experiment 3 (ex3) 10 g

[0143]

[0144] FIG. 9 is a scanning electron microscope (SEM) image of an anticancer substance according to Experimental Examples 1 to 3 of the present application, and FIG. 10 is a diagram showing the particle size and distribution of an anticancer substance according to Experimental Examples 1 to 3 of the present application.

[0145] Referring to Fig. 9, it can be seen that the particles are aggregated in Experimental Example 3 (ex3), which has the highest amount of gallium.

[0146] Referring to FIG. 10, it can be confirmed that when the amount of gallium is 1 g to 10 g according to Experimental Examples 1 to 3 (ex1~ex3), the particle diameter of the manufactured anticancer substance (20) is about 200 nm.

[0147] Thus, when the amount of gallium according to the above experimental example 3 (ex3) is less than 10 g, uniform dispersibility can be demonstrated at a particle diameter of about 200 nm of the anticancer substance (20).

[0148]

[0149] FIG. 11 is a diagram showing the dynamic light scattering (DLS) of anticancer substances according to Experimental Examples 1 to 3 of the present application, and FIG. 12 is a diagram showing the zeta potential of anticancer substances according to Experimental Examples 1 to 3 of the present application.

[0150] Referring to FIG. 11, it can be confirmed that the dynamic light scattering (DLS) of the manufactured anticancer substance (20) is similar when the amount of gallium is 1 g to 10 g according to Experimental Examples 1 to 3 (ex1~ex3).

[0151] Referring to FIG. 12, it can be seen that the zeta potential of the manufactured anticancer substance (20) is highest when the amount of gallium is increased from 1 g to 5 g according to Experimental Example 1 and Experimental Example 2 (ex1, ex2).

[0152] On the other hand, it can be seen that when the amount of gallium exceeds the boundary of 5 g according to Experimental Example 2 (ex2), that is, when the amount of gallium increases to 10 g according to Experimental Example 3 (ex3), the zeta potential actually decreases.

[0153] Thus, according to the above experimental example 2 (ex2), the critical significance of the case where the amount of gallium is 5 g can be proven, and the excellent dispersibility of the anticancer substance (ex2) according to the above experimental example 2 can be proven.

[0154]

[0155] FIG. 13 is a diagram showing (a) a transmission electron microscope (TEM) image and (b to e) scanning transmission electron microscope (SETM) images of a hydrogel ink for anticancer and tissue regeneration according to Experimental Example 3 of the present application.

[0156] Referring to FIG. 13(a), it can be seen that the diameter of one particle of the anticancer substance (20) included in the hydrogel ink (ex3) for anticancer and tissue regeneration according to Experimental Example 3 is about 200 nm, and that a transparent gallium oxide film is formed on the surface of the anticancer substance (20).

[0157] Additionally, referring to FIG. 13(b~e), carbon (C), oxygen (O), and silicon (Si) can be identified along with gallium (Ga), which is the anticancer substance (20), in the hydrogel ink (ex3) for anticancer and tissue regeneration according to Experimental Example 3.

[0158]

[0159] FIG. 14 is a drawing showing photographs (a~d) before mixing the curing agent and (e~h) after mixing the curing agent according to experimental examples of the present application.

[0160] Referring to the functional hydrogel (10) before mixing the curing agent shown in FIG. 14(a) and the hydrogel ink (100) for anticancer and tissue regeneration before mixing the curing agent shown in FIG. 14(b-d), it can be seen that the curing agent is in a non-mixed, flowing liquid state.

[0161] On the other hand, by referring to the functional hydrogel (10) after mixing the curing agent shown in FIG. 14(e) and the semi-solid hydrogel ink after mixing the curing agent shown in FIG. 14(f~h), it can be confirmed that the curing agent is mixed and is in a semi-solid state that does not flow down.

[0162] Thus, it can be seen that when the above-mentioned curing agent is mixed, it can be converted from a liquid state to a semi-solid state.

[0163]

[0164] FIG. 15 is a figure showing the viscosity according to Experimental Examples 1 to 3 of the present application, and FIG. 16 is a figure showing the loss modulus and storage modulus according to Experimental Examples 1 to 3 of the present application.

[0165] Referring to FIGS. 15 and 16, in the functional hydrogel (FSA, 10), the functional hydrogel (FSA, 10), the hardened support (DFSA) in which DNA is mixed as a tissue regeneration material (30) with the functional hydrogel (FSA, 10), the hardened support (GFSA, ex1~ex3) in which an anticancer substance (20) according to Experimental Examples 1 to 3 is mixed as the functional hydrogel (FSA, 10), and the anticancer substance (20) and the tissue regeneration material (30) according to Experimental Examples 1 to 3 are mixed as the functional hydrogel (FSA, 10) with the hardened hydrogel support (CFSA, ex1~ex3), it can be seen that DNA is included as the tissue regeneration material (30), and as the amount of gallium increases, the viscosity, loss modulus, and storage modulus increase.

[0166] Thus, it can be demonstrated that as the amount of the anticancer substance (20) increases, the viscosity and elasticity of the anticancer and tissue regeneration hydrogel support produced from the anticancer and tissue regeneration hydrogel ink (100) increase.

[0167]

[0168] FIG. 17 is a drawing showing a photograph of a printed material according to Experimental Example 2 of the present application.

[0169] It can be seen that the functional hydrogel (FSA, 10) according to Experimental Example 2 of FIG. 17(a), the cured support (GFSA) in which the functional hydrogel (FSA, 10) and the anticancer substance (20) according to Experimental Example 2 of FIG. 17(b), and the hydrogel support (CFSA) for anticancer and tissue regeneration in which the functional hydrogel (FSA, 10), the anticancer substance (20), and the tissue regeneration substance (30) according to Experimental Example 2 of FIG. 17(c) are mixed and cured are all manufactured as printed materials using a 3D printer.

[0170] Thus, according to the above experimental example 2 (ex2), it can be seen that when the amount of gallium is 5 g, it can be manufactured as a printed product through a 3D printer.

[0171]

[0172] FIG. 18 is a diagram showing x-ray diffraction (XRD) according to Experimental Examples 1 to 3 of the present application.

[0173] Referring to Fig. 18, since the functional hydrogel (FSA, 10) is a sodium alginate-based material, it can be confirmed that the functional hydrogel (FSA, 10) and sodium alginate (SA) exhibit the same peak.

[0174] In addition, referring to Fig. 18, according to the above experimental example 1 (ex1), when the amount of gallium is 1 g, it can be seen that the gallium peak is weak because the gallium content is too low.

[0175] On the other hand, referring to Fig. 18, according to Experimental Example 2 and Experimental Example 3 (ex2, ex3), when the amount of gallium is 5 g or more to 1 g or less, the gallium peak appears clearly, and as the amount of gallium increases, a clearer gallium peak can be observed.

[0176] Thus, it can be proven that for the anticancer activity of the anticancer substance (20) contained in the hydrogel ink (100) for anticancer and tissue regeneration and the hydrogel support for anticancer and tissue regeneration manufactured from the hydrogel ink (100) for anticancer and tissue regeneration, an amount of gallium exceeding 1 g according to Experimental Example 1 (ex1) is required.

[0177]

[0178] FIG. 19 is a diagram showing the tissue regeneration material release behavior of a hydrogel support for anticancer and tissue regeneration according to Experimental Examples 1 to 3 of the present application.

[0179] Referring to FIG. 19, the hydrogel support for anticancer and tissue regeneration (ex1~ex3) according to Experimental Examples 1 to 3 was immersed in 37°C Dulbecco's phosphate-buffered saline (DPBS), and the absorbance was analyzed through a nanodrop after obtaining the Dulbecco's phosphate-buffered saline (DPBS) over time. As a result, it was confirmed that the release behavior of DNA into the tissue regeneration material (30) slowed down as the amount of gallium increased.

[0180] Thus, it can be proven that as the amount of gallium increases, the release of the tissue regeneration material (30) slows down.

[0181]

[0182] FIG. 20 is a diagram showing the photothermal reaction of a hydrogel support for anticancer and tissue regeneration according to Experimental Examples 1 to 3 of the present application.

[0183] Referring to FIG. 20, according to Experimental Example 2 and Experimental Example 3 (ex2, ex3), when the amount of gallium is 5 g or more to 10 g or less, an excellent photothermal reaction can be confirmed.

[0184] Thus, an excellent photothermal reaction can be demonstrated when the amount of gallium according to Experimental Example 1 (ex1) is greater than 1 g.

[0185]

[0186] FIG. 21 is a diagram showing the cytotoxicity of hydrogel supports for anticancer and tissue regeneration according to Experimental Examples 1 to 3 of the present application.

[0187] Referring to FIG. 21, cytotoxicity was confirmed using cell culture media in which the hydrogel supports for anticancer and tissue regeneration (ex1 to ex3) according to Experimental Examples 1 to 3 were eluted at 50°C for 3 days. As a result, toxicity was confirmed at sonication times of 30 seconds, 1 minute, and 5 minutes, when the amount of gallium was 10 g.

[0188] Thus, when the amount of gallium according to Experimental Example 3 (ex3) is less than 10 g, the hydrogel support for anticancer and tissue regeneration can be proven to be non-toxic.

[0189] In addition, referring to Fig. 21, excellent cell viability can be confirmed at ultrasonic treatment times of 30 seconds, 1 minute, and 5 minutes when the amount of gallium according to Experimental Example 2 (ex2) is 5 g.

[0190] In particular, when the ultrasonic treatment time is 1 minute, according to Experimental Example 1 and Experimental Example 2 (ex1, ex2), when the amount of gallium is increased from 1 g to 5 g, the cell viability increases; on the other hand, when the amount of gallium exceeds the 5 g amount according to Experimental Example 2 (ex2), that is, when the amount of gallium is increased to 10 g according to Experimental Example 3 (ex3), the cell viability decreases.

[0191] Thus, according to the above experimental example 2 (ex2), the critical significance of the case where the amount of gallium is 5 g can be proven, and the excellent cell viability of the anticancer substance (ex2) according to the above experimental example 2 can be proven.

[0192]

[0193] Although the present application has been described in detail using preferred embodiments, the scope of the present application is not limited to specific embodiments and should be interpreted by the appended claims. Furthermore, those skilled in the art will understand that many modifications and variations are possible without departing from the scope of the present application.

Claims

1. A step of preparing an ink source by mixing a functional hydrogel and a tissue regeneration material; A step of preparing a hydrogel ink for anticancer and tissue regeneration by adding an anticancer substance to the above ink source; A step of preparing a semi-solid hydrogel ink by mixing the above-mentioned hydrogel ink for anticancer and tissue regeneration and a curing agent; and A method for manufacturing a hydrogel support for anticancer and tissue regeneration, comprising the step of printing and curing the above-mentioned semi-solid hydrogel ink to manufacture a hydrogel support for anticancer and tissue regeneration.

2. In Paragraph 1, The above functional hydrogel is, A step of preparing a gelling polymer source by dissolving a gelling polymer; and A method for manufacturing a hydrogel support for anticancer and tissue regeneration, comprising the step of manufacturing the functional hydrogel by reacting the above-mentioned gelling polymer source with a functionalizing agent comprising epoxy groups and silane groups.

3. In Paragraph 2, The above gelling polymer comprises alginate, and A method for preparing a hydrogel scaffold for anticancer and tissue regeneration, wherein the above-mentioned functionalizing agent comprises 3-glycidoxypropyl trimethoxysilane (GPTMS).

4. In Paragraph 1, The above anticancer substance includes gallium, and A method for manufacturing a hydrogel support for anticancer and tissue regeneration, comprising providing the gallium in an amount of more than 1 g and less than 10 g per 100 g of water.

5. In Paragraph 4, A method for manufacturing a hydrogel support for anticancer and tissue regeneration, comprising increasing viscosity and elasticity and slowing down the release of the tissue regeneration material as the amount of gallium increases.

6. In Paragraph 1, The above anticancer substance is, Step of preparing the first anticancer source; A step of heat-treating the above-mentioned first anticancer source; A step of preparing a second anticancer source by ultrasonically treating the heat-treated first anticancer source in a low-temperature atmosphere; and A method for manufacturing a hydrogel support for anticancer and tissue regeneration, comprising the step of manufacturing the anticancer substance by rapidly freeze-drying the second anticancer source.

7. In Paragraph 6, The above-mentioned first anticancer source is in liquid form, and A method for manufacturing a hydrogel support for anticancer and tissue regeneration, comprising the second anticancer source being in powder form.

8. In Paragraph 1, A method for manufacturing a hydrogel support for anticancer and tissue regeneration, wherein the above-mentioned curing agent comprises calcium chloride.

9. Functional hydrogel; An anticancer substance supported on the above functional hydrogel and acting as an anticancer agent through a photothermal reaction; and A hydrogel support for anticancer and tissue regeneration, comprising a tissue regeneration material supported on the above functional hydrogel and regenerating tissue after the anticancer action of the above anticancer substance.

10. In Paragraph 9, The above anticancer substance comprises increasing the viscosity and elasticity of the functional hydrogel and slowing down the release of the tissue regeneration substance, for an anticancer and tissue regeneration hydrogel support.

11. In Paragraph 9, The above functional hydrogel comprises alginate functionalized with 3-glycidoxypropyltrimethoxysilane (GPTMS), and The above anticancer substance includes gallium, and The above tissue regeneration material is a hydrogel support for anticancer and tissue regeneration comprising DNA (deoxyribonucleic acid).

12. A step of providing a hydrogel scaffold for anticancer and tissue regeneration according to claim 9 to cancer tissue; A step in which the anticancer substance undergoes a photothermal reaction by light irradiation, thereby acting as an anticancer agent in the cancer tissue; and A tissue treatment method using a hydrogel scaffold for anticancer and tissue regeneration, comprising the step of regenerating tissue in the tissue using the tissue regeneration material after the anticancer action of the anticancer substance.

13. In Paragraph 12, A tissue treatment method using a hydrogel support for anticancer and tissue regeneration, comprising controlling the release rate of the tissue regeneration material by the anticancer material.

14. Functional hydrogel; An anticancer substance supported on the above functional hydrogel and acting as an anticancer agent through a photothermal reaction; and Hydrogel ink for anticancer and tissue regeneration, comprising a tissue regeneration material that regenerates tissue in combination with the above-mentioned functional hydrogel.